NASDAQ$PSNL
Personalis Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Personalis reported a 3% increase in quarterly revenue, driven by a 102% increase in revenue from biopharma and other customers, excluding VA MVP, which was partially offset by a decrease in VA MVP revenue.
Personalis, Inc. reported financial results for the fourth quarter and full year ended December 31, 2021. The company's quarterly revenue increased by 3% compared to the fourth quarter of 2020. Revenue from biopharma and other customers, excluding the VA MVP, increased by 102%.
- Reported quarterly revenue of $20.7 million, a 3% increase compared to Q4 2020.
- Revenue from biopharma and other customers, excluding the VA MVP, increased by 102%.
- Launched tumor-informed liquid biopsy assay, NeXT PersonalTM in December 2021.
- Received first customer order for NeXT Personal in the first quarter of 2022 from a top global pharmaceutical company.
Headline financials
Revenue & EPS history
Personalis · Revenue · Quarterly
$20.7M
Revenue by segment
Personalis · $18.2M total across 4 segments · Q3 2023
- Pharma tests and services$8M—43.8%
- Enterprise sales$7.81M—42.8%
- Population sequencing$2.4M—13.2%
- Other$38K—0.2%
Forward guidance
Personalis expects total company revenue to be approximately $67.0 million for the full year of 2022. Revenue from biopharma and all other customers, excluding the VA MVP, is expected to be approximately $60.0 million, an increase of 51% compared with 2021. Net loss is expected to be in the range of $110.0 million to $115.0 million.
Tailwinds
- Total company revenue is expected to be approximately $67.0 million.
- Revenue from biopharma and all other customers, excluding the VA MVP, is expected to be approximately $60.0 million.
- Revenue from biopharma and all other customers, excluding the VA MVP, is expected to increase of 51% compared with 2021.
Headwinds
- Net loss is expected to be in the range of $110.0 million to $115.0 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+1.0%
Avg return
Earnings day
+1.5%
Avg return
5 days after
+1.5%
Avg return
30 days after
59%
16 / 27 earnings
Positive
+19.9%
Q1 2025
Best reaction
-23.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.2% | -0.7% | +76.6% | |
| Q4 2025 | +0.6% | -1.1% | -29.8% | |
| Q3 2025 | -12.3% | -1.1% | +9.5% | |
| Q1 2025 | +19.9% | +27.5% | +30.3% | |
| Q4 2024 | -2.4% | +5.9% | -14.6% | |
| Q3 2024 | -23.4% | -12.8% | -26.4% | |
| Q2 2024 | +7.2% | +34.7% | +67.8% | |
| Q1 2024 | +4.4% | -2.5% | -14.6% | |
| Q4 2023 | +3.3% | +16.0% | -0.7% | |
| Q3 2023 | +10.4% | -3.8% | +39.6% | |
| Q2 2023 | +4.7% | +7.9% | -17.9% | |
| Q1 2023 | +4.5% | +3.2% | -6.4% | |
| Q4 2022 | -7.2% | -5.3% | -18.2% | |
| Q3 2022 | -1.5% | -15.3% | +4.7% | |
| Q2 2022 | +10.6% | +11.1% | -21.4% | |
| Q1 2022 | -7.2% | -24.8% | -34.1% | |
| Q4 2021 | +12.2% | +11.0% | -14.4% | |
| Q3 2021 | +2.6% | -5.4% | -38.9% | |
| Q2 2021 | +10.2% | +4.1% | +12.4% | |
| Q1 2021 | -0.6% | -9.9% | -4.3% | |
| Q4 2020 | -11.1% | -10.8% | -36.3% | |
| Q3 2020 | +0.1% | -0.3% | +13.6% | |
| Q2 2020 | -2.4% | -3.7% | -4.7% | |
| Q1 2020 | +4.6% | +7.2% | +27.6% | |
| Q4 2019 | +17.5% | +27.5% | +52.8% | |
| Q3 2019 | +0.2% | -12.7% | +0.3% | |
| Q2 2019 | -15.6% | -6.2% | -11.6% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro